OLR1 and non-small cell lung carcinoma: The expression level of sLOX-1 in the serum of patients with stages I–II and III–IV NSCLC was significantly higher than that of healthy controls (p < 0.001), and the expression level of sLOX-1 in the stage III–IV NSCLC group were higher than the stage I–II NSCLC group (p < 0.001; Figure 1(a)).